Marlies De Bock

Marlies De Bock

Auto-generated profile, based on publicly available information

Marlies De Bock

Department of Medical Oncology

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 August 2018 in Case Reports in Dermatology
Verified
Journal Article
Open access
PDF file
MBMarlies De Bock
Marlies De Bock
EHEva Hulstaert
Eva Hulstaert
VKVibeke Kruse
Vibeke Kruse
LBLieve Brochez
Lieve Brochez
Objective: The incidence of immune-related adverse events is growing as the use of checkpoint inhibitors is exponentially increasing. Cutaneous adverse events are among the most frequent immune-related adverse events. The purpose of this case report and literature review is to highlight psoriasis as a potential adverse event with need for early recognition. Case Report and Literature Review: We describe the case of a 65-year-old woman with psoriasis exacerbation while treated with nivolumab (anti-PD-1) for a stage IV melanoma. She had a history of scalp psoriasis but she presented with psoriatic lesions on both lower and upper limbs. Our patient was treated with topical steroids. So far, 34 other cases with an exacerbation of psoriasis during treatment with anti-PDL-1 or PD-1 therapy have been reported in the literature. A broad range of therapies are described, without any available guidelines for this particular condition. Conclusion: Psoriasis exacerbation is an established side effect of PD-1/PDL-1 checkpoint inhibitors with 35 reported cases. Early recognition and management are challenging as there are no clear guidelines available. A close collaboration between oncologist and dermatologist is mandatory to manage this immune-related adverse event.

21 March 2022 in Logopedics Phoniatrics Vocology
Verified
Journal Article
Open access
CACassandra Alighieri
Cassandra Alighieri
MBMarlies De Bock
Marlies De Bock
GGGeorge Galiwango
George Galiwango
DSDaniel Sseremba
Daniel Sseremba
KLKristiane Van Lierde
Kristiane Van Lierde
Objective: This paper describes the current situation of the provision of speech-language services in East Africa. An overview of the educational opportunities, workforce density, communication rehabilitation planning, caseload, and ethical and/or cultural challenges is provided. Method: A narrative review was performed. All papers referring to communication disorders in East African countries were identified from EMBASE, PubMed, ISI Web of Science: Science Citation Index Expanded, and ISI Web of Science: Conference Proceedings Citation Index-Science using the following search terms: speech therapy, speech pathology, speech-language pathology, speech-language rehabilitation, speech-language therapy, logopedics, East Africa, communication disorders, communication difficulties. Two concepts were combined with a Boolean operator ‘AND’. Results: At present, there is an alarming shortage of speech-language pathologists in East Africa. This issue is mainly related to the limited availability of educational programs in speech-language pathology. Although more and more universities are beginning to offer such educational programs, the number of available speech-language pathologists is still too low to meet the needs of all children with communication disorders. In addition, speech-language pathologists are often faced with different cultural and ethical obstacles when they provide intervention to East African children with communication disorders. These speech-language pathologists are therefore challenged to take a broader view of their role as a therapist. These alternative roles often include training of other individuals in the context of community-based rehabilitation. Conclusion: In the future, it will be important to carefully consider the development of sustainable learning opportunities in East African contexts. Initiatives, for example, “train-the-trainer” workshops, are needed to support the speechlanguage pathologists. Existing models like the communication disability model can aid to create holistic frameworks for the development of sustainable speech-language services in the East African countries.

23 June 2019 in Acta Clinica Belgica
Verified
Journal Article
Closed access
KCKaren Couvreur
Karen Couvreur
CJCeline Jacobs
Celine Jacobs
BMBock Marlies
Bock Marlies
DRD’hondt Randal
D’hondt Randal
DPDeron Philippe
Deron Philippe
RSRottey Sylvie
Rottey Sylvie
Introduction: Adenoid cystic carcinoma (ACC) of the head and neck is a rare malignancy of the salivary glands that accounts for approximately 10% of salivary gland carcinoma. Despite aggressive local therapy, local recurrence and distant metastases occur frequently. Response rates (RR) to potential curative and palliative chemotherapy are limited, so new strategies are needed. Case reports: We describe five case reports of patients with unresectable locally advanced or metastatic ACC of the head and neck who have been treated with sorafenib, a multi-tyrosine kinase inhibitor (mTKI). Results: In this case series, we found that three out of five patients treated with sorafenib survived, respectively, 16, 35 and 35 months. Two patients showed a partial response (PR) and one patient had a prolonged stable disease (SD) for almost three years. Grade 3 adverse events (AE) occur under sorafenib so adequate toxicity management is essential. This retrospective case series hints towards the possibility of clinical benefit for treating ACC patients with sorafenib. Efficacy of sorafenib should be studied in a prospective-randomized clinical trial which is a challenging task due to the rarity of the disease.

24 June 2020 in Acta Clinica Belgica
Verified
Journal Article
Closed access
TVTine Vanlancker
Tine Vanlancker
BSBarbara Stragier
Barbara Stragier
MBMarlies De Bock
Marlies De Bock
Paraneoplastic Raynaud’s phenomenon is a rare complication occurring in patients with advanced cancer. We present a case of a patient with breast cancer and presenting with acrocyanosis evolving in...

4 March 2025 in Acta Clinica Belgica
Verified
Journal Article
Closed access
VNVandemaele N.
Vandemaele N.
SBStragier B.
Stragier B.
TATamsin A.
Tamsin A.
DMDe Bock M.
De Bock M.
To illustrate the diagnostic challenges, as well as the importance of early recognition of rare immunotherapy-induced complications, presenting a case and literature of sarcoid-like granulomatous reaction. This report presents a case of asymptomatic hypercalcemia, revealing a sarcoid-like granulomatosis in a patient with metastastatic melanoma, treated with an immune checkpoint inhibitor (ICI). In the discussion, an overview of the existing literature is provided through a PubMed search. Thorough investigations are essential to rule out disease progression and other possible explanations. Ultimately, biopsy with extensive staining led to the diagnosis of sarcoid-like granulomatosis. As there is no consensus in treatment, we suggest a case-by-case assessment, if possible by discussion within the multidisciplinary treatment team, to decide discontinuation of the causal ICI-therapy or the use of systemic steroids as supportive therapy. This case demonstrates the importance of a broad differential diagnosis when identifying an asymptomatic hypercalcemia as well as new CT-graphic lesions, since the diagnosis of sarcoid-like granulomatosis can avoid not only unnecessary changes in treatment plans, avoiding toxicity, but also be a sign of good prognosis.